TuisINCY • NASDAQ
add
Incyte Corp
Vorige sluiting
$73,13
Dagwisseling
$69,53 - $72,60
Jaarwisseling
$50,35 - $83,94
Markkapitalisasie
13,59 mjd USD
Gemiddelde volume
1,79 m
P/V-verhouding
504,04
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,14 mjd | 23,81% |
Bedryfskoste | 308,47 m | 15,48% |
Netto inkomste | 106,46 m | -37,84% |
Netto winsgrens | 9,36 | -49,79% |
Wins per aandeel | 1,07 | -2,73% |
EBITDA | 192,75 m | -18,48% |
Effektiewe belastingkoers | 31,99% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,77 mjd | -49,53% |
Totale bates | 5,01 mjd | -21,54% |
Totale aanspreeklikheid | 1,84 mjd | 26,39% |
Totale ekwiteit | 3,17 mjd | — |
Uitstaande aandele | 192,65 m | — |
Prys om te bespreek | 4,45 | — |
Opbrengs op bates | 8,80% | — |
Opbrengs op kapitaal | 13,64% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 106,46 m | -37,84% |
Kontant van bedrywe | 310,87 m | 110,28% |
Kontant van beleggings | 38,27 m | 322,67% |
Kontant van finansiering | -32,35 m | 13,17% |
Netto kontantverandering | 316,92 m | 229,77% |
Beskikbare kontantvloei | 367,45 m | 138,29% |
Meer oor
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland.
The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
Gestig
2002
Hoofkwartier
Webwerf
Werknemers
2 524
